Giles Wilson Buys 197 Shares of Dr. Martens (LON:DOCS) Stock

Dr. Martens plc (LON:DOCS) insider Giles Wilson bought 197 shares of Dr. Martens stock in a transaction dated Thursday, December 11th. The shares were bought at an average price of GBX 76 per share, for a total transaction of £149.72.

Giles Wilson also recently made the following trade(s):

• On Tuesday, November 11th, Giles Wilson purchased 176 shares of Dr. Martens stock. The shares were bought at an average cost of GBX 85 per share, for a total transaction of £149.60.
• On Monday, October 13th, Giles Wilson purchased 167 shares of Dr. Martens stock. The stock was bought at an average cost of GBX 89 per share, with a total value of £148.63.
• On Wednesday, October 8th, Giles Wilson acquired 114 shares of Dr. Martens stock. The stock was bought at an average price of GBX 90 per share, with a total value of £102.60.

Dr. Martens Trading Up 0.6%

DOCS traded up GBX 0.50 during mid-day trading on Friday, reaching GBX 77.45. The stock had a trading volume of 6,999,042 shares, compared to its average volume of 2,302,026. The stock has a market capitalization of £748.44 million, a P/E ratio of 45.56, a P/E/G ratio of 6.40 and a beta of 0.11. The company has a debt-to-equity ratio of 127.27, a quick ratio of 1.13 and a current ratio of 2.85. The firm’s fifty day simple moving average is GBX 85.14 and its two-hundred day simple moving average is GBX 82.29. Dr. Martens plc has a 52 week low of GBX 43.02 and a 52 week high of GBX 100.87.

Dr. Martens (LON:DOCS) last released its earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. On average, equities analysts predict that Dr. Martens plc will post 2.5809394 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on DOCS. Peel Hunt restated a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Berenberg Bank reissued a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 27th. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Dr. Martens has a consensus rating of “Moderate Buy” and an average target price of GBX 6,000.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history.